Literature DB >> 1981793

Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites.

M Fujiwara1, K Mitsui, I Yamamoto.   

Abstract

Mixed lymphocytes reactions (MLR) and concanavalin A (Con A)- or phytohemagglutinin (PHA)-stimulated proliferative responses were dose-dependently inhibited by salazosulfapyridine (SASP) and cyclosporin A (CsA) in the concentration ranges of 1 x 10(-5) -5 x 10(-4) M and 10-1000 ng/ml, respectively. Such a significant inhibition was not observed with metabolites of SASP, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA). In addition, SASP and CsA inhibited the production of interleukin 2 (IL-2) from splenocytes in these experiments. The inhibitory effect of CsA on IL-2 production practically correlated with that on proliferative responses, whereas SASP showed a less marked inhibitory effect on IL-2 production than on proliferative responses. Neither SP nor 5-ASA inhibited the IL-2 production. In the Con A-induced proliferative response, SASP showed a full inhibition even when added after 4-8 hr of culture, but CsA did not. The splenocytes that were pulsed with Con A for 4 hr could proliferate in response to Con A-supernatant or purified IL-2. CsA exhibited the inhibitory activity only when present during the time of Con A-pulsing, while SASP acted on the subsequent stage of the response, exerting its inhibitory effect. These findings suggest that SASP down-regulates the immune response by a mechanism apparently distinct from that of CsA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981793     DOI: 10.1254/jjp.54.121

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  9 in total

Review 1.  Sulfasalazine: a review of its use in the management of rheumatoid arthritis.

Authors:  Greg L Plosker; Katherine F Croom
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Authors:  C Wahl; S Liptay; G Adler; R M Schmid
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 3.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

4.  The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4⁺CD25⁺ regulatory T cells.

Authors:  Ji Seon Oh; Yong-Gil Kim; Seung Geun Lee; Min Wook So; Seung Won Choi; Chang-Keun Lee; Bin Yoo
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

5.  Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine.

Authors:  S Liptay; M Bachem; G Häcker; G Adler; K M Debatin; R M Schmid
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats.

Authors:  Semih Gorgulu; Gokhan Yagci; Nihat Kaymakcioglu; Murat Ozkara; Bulent Kurt; Ayhan Ozcan; Omer Kaya; Serdar Sadir; Turgut Tufan
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

7.  Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds.

Authors:  G Carlin; R Djursäter; G Smedegård
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

8.  N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

Authors:  Shunichi Kumagai; Fusao Komada; Tomoko Kita; Akio Morinobu; Shoichi Ozaki; Hiroshi Ishida; Hajime Sano; Tsukasa Matsubara; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

9.  Mesalazine-induced myocarditis: a case report.

Authors:  Shiva T Radhakrishnan; Aruchuna Mohanaruban; Sami Hoque
Journal:  J Med Case Rep       Date:  2018-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.